basic sceince research

BASIC SCIENCE RESEARCH PROGRAM

Innovative Techniques Through Basic Science Research

The Basic Science Research Program (BSRP) focuses on defining prostate cancer-specific molecular alterations that would lead to better understanding of the causes of prostate cancer. Prostate cancer gene discovery and biology focused research efforts are complemented by collaborations from the CPDR's Clinical Research and Multicenter National Database programs, accelerating the evaluations of new biomarkers and therapeutic targets with potential in enhancing the management of prostate cancer.

The program is led by Dr. Shiv Srivastava, who is an internationally recognized leader in the field of cancer research. Strong collaborations with Dr. Isabell A. Sesterhenn from JPC (formerly AFIP) and the CPDR-Clinical Research Program at WRNMMC (formerly WRAMC) remains the mainstay of the highly productive translational research initiatives. Due to the reorganization of the AFIP as JPC, Dr. Sesterhenn's laboratory has been integrated within the CPDR-BSRP as of August 2011.

 

MISSION

  • Discovery of frequent and potentially causal prostate cancer gene alterations using cutting edge technologies and well annotated and precisely processed bio-specimens
  • Evaluation of cancer biology of prostate cancer relevant genes or proteins using established and new experimental models
  • Development of new molecular strategies for improving prostate cancer diagnosis (more cancer specific markers than PSA) and prognosis Contents are Proprietary and Provided for CPDR Scientific Advisory Committee Review Only 1: 5
  • Delineation of hormonal mechanisms involved in prostate cancer onset or progression
  • Development and evaluation of novel molecular therapeutic agents for prostate cancer
  • Identification of molecular determinants of prostate cancer susceptibility in high-risk groups such as African-Americans
  • Development and maintenance of long-term molecular specimen resources for translational investigations at CPDR and collaborations at other institutions
  • Education and training of next generation of basic science and translational researchers in prostate cancer

 

Education and training of medical and graduate students, post-doctoral fellows, residents and visiting scientists in CaP research Two of the major activities of the BRP research program include investigator-initiated research and development of unique bio-resources critical for research at CPDR and in the CaP field.

BSRP Leadership | Gene Expression Data | Research Achievements | BSRP Staff

CURRENT EVENTS


WRNMMC UsToo!
Quarterly Guest Speakers


Tschlitz

Dr. Philip Arlen
National Cancer Institute

Topic: "Prostate Cancer: An Overview and Update of Novel Treatment Modalities"
There have been remarkable advances in the therapy for prostate cancer over the past decade. We will be discussing these advances as well as new treatment options in clinical trials.

Date: Thursday 5 May 2016
Time: 1900-2030
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).

Read the MAY 2016 WRNMMC UsToo! Newsletter

Go to WRNMMC UsToo! Newsletter Archive

 

February 2, 2016

CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar

Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.

Read Full Article

 

January 11, 2016

A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men

The USU, Walter Reed-Bethesda and JPC collaborative team, through comprehensive evaluations of matched cohorts of African American and Caucasian American prostate cancers, previously established a higher frequency of ERG alterations in Caucasians (50-70%) and its significantly lower frequency in African Americans (20-25%). These intriguing observations actually provided the rational for the current study focusing on whole genome evaluations of prostate cancers from these two patient populations.

Read Full Article